Quick Answer
SANGAMO THERAPEUTICS, INC reported Total Revenue of $39.55 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $39.55M -31.6% |
$57.80M -67.2% |
$176.23M +58.3% |
$111.30M +0.5% |
$110.70M -6.3% |
$118.19M +15.4% |
| Revenue (ASC 606) | $39.55M -31.6% |
$57.80M -67.2% |
$176.23M +58.3% |
$111.30M +0.5% |
$110.70M -6.3% |
$118.19M +15.4% |
| Net Income | -$122.93M -25.5% |
-$97.94M +62.0% |
-$257.83M -34.1% |
-$192.28M -7.8% |
-$178.29M -47.3% |
-$121.00M -27.1% |
| Diluted EPS | -$0.44 +10.2% |
-$0.49 +66.9% |
-$1.48 -18.4% |
-$1.25 -1.6% |
-$1.23 -36.7% |
-$0.90 -5.9% |
| Total Assets | $59.74M -41.2% |
$101.64M -38.5% |
$165.32M -70.6% |
$562.51M -22.1% |
$721.92M -23.1% |
$938.55M +47.2% |
| Cash and Equivalents | $20.95M -50.0% |
$41.92M -7.3% |
$45.20M -55.0% |
$100.44M -43.8% |
$178.87M +36.2% |
$131.33M +63.3% |
| Stockholders Equity | -$14.27M -162.7% |
$22.77M -72.5% |
$82.89M -71.9% |
$294.96M -21.4% |
$375.34M -24.7% |
$498.23M +15.2% |
| R&D Expense | $112.67M +1.0% |
$111.52M -52.4% |
$234.06M -6.3% |
$249.90M +8.3% |
$230.82M +27.8% |
$180.65M +23.8% |
| Operating Income | -$121.24M -16.6% |
-$103.97M +62.1% |
-$274.00M -36.1% |
-$201.28M -9.8% |
-$183.34M -41.5% |
-$129.55M -23.2% |
| Shares Outstanding | 350.69M +64.8% |
212.84M +19.5% |
178.13M +6.8% |
166.79M +14.3% |
145.92M +2.7% |
142.06M +22.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $581.0K | -98.8% | -96.8% |
| Revenue (ASC 606) | September 30, 2025 | $581.0K | -98.8% | -96.8% |
| Net Income | September 30, 2025 | -$34.93M | -427.3% | -74.8% |
| Diluted EPS | September 30, 2025 | -$0.11 | -375.0% | -37.5% |
| Total Assets | September 30, 2025 | $88.64M | -20.3% | -9.1% |
| Cash and Equivalents | September 30, 2025 | $29.62M | -24.5% | -22.8% |
| Stockholders Equity | September 30, 2025 | $6.24M | -84.0% | -68.2% |
| R&D Expense | September 30, 2025 | $28.14M | +1.5% | +3.9% |
| Operating Income | September 30, 2025 | -$35.55M | -434.4% | -99.1% |
| Shares Outstanding | September 30, 2018 | 101.84M | +21.1% | +0.2% |
- SANGAMO THERAPEUTICS, INC reported Total Revenue of $39.55 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -31.6% in Total Revenue compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Revenue (ASC 606) of $39.55 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -31.6% in Revenue (ASC 606) compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Net Income of -$122.93 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -25.5% in Net Income compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Diluted EPS of $0.44 per share (loss) for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +10.2% in Diluted EPS compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Total Assets of $59.74 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -41.2% in Total Assets compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Cash and Equivalents of $20.95 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -50.0% in Cash and Equivalents compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Stockholders Equity of -$14.27 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -162.7% in Stockholders Equity compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported R&D Expense of $112.67 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +1.0% in R&D Expense compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Operating Income of -$121.24 million for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -16.6% in Operating Income compared to the prior fiscal year.
- SANGAMO THERAPEUTICS, INC reported Shares Outstanding of 350.69 million shares for fiscal year 2025.
- SANGAMO THERAPEUTICS, INC showed an increase of +64.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: